Easywell Biomedicals, Inc. (TPEX:1799)

Market Cap	7.43B
Revenue (ttm)	540.44M
Net Income (ttm)	-97.47M
Shares Out	124.69M
EPS (ttm)	-0.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	532,260
Average Volume	254,976
Open	64.20
Previous Close	62.50
Day's Range	59.50 - 65.20
52-Week Range	49.90 - 233.00
Beta	0.48
RSI	46.39
Earnings Date	May 8, 2025

About Easywell Biomedicals

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1799

Financial Performance

In 2024, Easywell Biomedicals's revenue was 540.44 million, an increase of 98.96% compared to the previous year's 271.63 million. Losses were -97.47 million, -32.70% less than in 2023.